Metoprolol added to standard care to prevent heart muscle damage
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This trial tests whether adding metoprolol (a beta-blocker) to usual care can prevent or slow cardiomyopathy (heart muscle weakness) in people with Duchenne muscular dystrophy (DMD). It also checks for safety, especially effects on heart rate and rhythm.
Summary written for real people, not researchers, by Clin2.
Who can take part
- A parent/legal guardian agrees in writing (and you can assent if you’re old enough) before any study steps
- You can take pills by mouth and are willing to take the study medicine as instructed for the whole study
- You have a confirmed diagnosis of DMD based on genetic test results or lab tests showing missing/damaged dystrophin protein
- You have been taking an ACE inhibitor (ACEi) medication at the required dose for at least 30 days
- You are not currently taking (and have not permanently used) any beta-blocker medication in the past
- Your heart health looks safe for this study: no pacemaker/ICD, no heart failure symptoms, no significant slow heart rhythm or certain heart block patterns, and ejection fraction is at least 57%
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new medicine called zeleciment rostudirsen can help ambulatory (walking) males with Duchenne muscular dystrophy (DMD). The medicine is given as an intravenous infusion (through a vein) every 4 weeks and works by helping the body produce a protective muscle protein.
This trial tests a heart medication called captopril in people with Duchenne muscular dystrophy who already have some early heart muscle changes. The goal is to see if it can help protect the heart.
This trial tests an experimental therapy for heart weakness caused by Duchenne muscular dystrophy. It aims to improve how heart cells handle calcium to protect heart function.
This trial tests a once-daily drug called mexiletine PR to see if it can help reduce muscle stiffness (myotonia) in people with myotonic dystrophy type 1 or 2. It may be a good option if you have a confirmed genetic diagnosis and are at least 16 years old.
This trial tests if a medicine that improves blood flow, combined with exercise, can help muscles in boys with Duchenne muscular dystrophy. It is for boys who can still walk and are on a stable steroid medication.
This trial tests a new cell-based treatment for Duchenne muscular dystrophy in adults who can no longer walk. The goal is to see if the therapy can help improve muscle function.
Hear when a new Muscular Dystrophy, Duchenne trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.